Investigational Drug Information for PF-06651600
✉ Email this page to a colleague
What is the development status for investigational drug PF-06651600?
PF-06651600 is an investigational drug.
There have been 35 clinical trials for PF-06651600.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 18th 2019.
The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Pfizer, Emma Guttman, and Icahn School of Medicine at Mount Sinai.
There is one US patent protecting this investigational drug and fifty-one international patents.
Summary for PF-06651600
| US Patents | 1 |
| International Patents | 51 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2019-07-18) |
| Vendors | 39 |
Recent Clinical Trials for PF-06651600
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults | Pfizer | Phase 1 |
| A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants | Pfizer | Phase 1 |
| Ritlecitinib in CTCL | Pfizer | Phase 2 |
Clinical Trial Summary for PF-06651600
Top disease conditions for PF-06651600
Top clinical trial sponsors for PF-06651600
US Patents for PF-06651600
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06651600 | ⤷ Sign Up | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06651600
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06651600 | Argentina | AR099363 | 2033-12-05 | ⤷ Sign Up |
| PF-06651600 | Australia | AU2014358792 | 2033-12-05 | ⤷ Sign Up |
| PF-06651600 | Brazil | BR112016012262 | 2033-12-05 | ⤷ Sign Up |
| PF-06651600 | Canada | CA2932425 | 2033-12-05 | ⤷ Sign Up |
| PF-06651600 | Chile | CL2016001216 | 2033-12-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
